“The refusal to authorize MDMA as a medication has done a huge favor to ‘underground’ therapy”
2024 was expected to be the year of the consolidation of the “psychedelic renaissance.” However, the FDA, the drug regulatory agency in the US, has rejected the approval of MDMA as a treatment for post-traumatic stress. José Carlos Bouso, scientific director of ICEERS and speaker at Fuertedélica, analyzes in this interview the causes behind this…
“Our research suggests that ayahuasca has an analgesic effect”
Rafael Guimarães dos Santos is a world-renowned expert in scientific research on ayahuasca. A disciple of Jordi Riba at Sant Pau Hospital, Dos Santos leads several cutting-edge investigations with ayahuasca, ibogaine, and ketamine within the Department of Neuroscience and Behavioral Sciences at the University of São Paulo. In this interview, the Brazilian researcher gives us…
“Drugs Saved Me From Sport”
In a world where drugs are viewed through the prism of prohibition, Eduardo Hidalgo emerges as a discordant voice that invites us to rethink our relationship with psychoactive substances. Known for his work as coordinator for more than a decade in the Madrid delegation of Energy Control and for his controversial work Sustainable Hedonism, Eduardo…
The United States Rejects the Approval of Therapeutic MDMA Use
In a controversial decision, the U.S. Food and Drug Administration (FDA) has decided not to approve the therapeutic use of MDMA for the treatment of post-traumatic stress disorder (PTSD) and other psychiatric disorders. This decision represents a significant setback in the field of mental health, limiting the therapeutic options available to millions of people suffering…
“Ketamine provides a detached and new perspective on oneself”
Estefanía Moreno will be part of the round table “Climbing Out of the Hole: Ketamine and Mental Health,” next Saturday, November 23rd, at Fuertedélica. Moreno is a doctor with training in Psychoneuroimmunology and Transpersonal Psychology, and she conducts ketamine-assisted psychotherapy at Clínica Synaptica, a pioneering center in Catalonia for psychedelic therapy. More than 240 patients…
From the Dance Floor to the Therapy Couch: A Brief History of MDMA
MDMA was first synthesized by Anton Köllisch at the pharmaceutical company Merck in Germany. The young German chemist developed 3,4-methylenedioxymethamphetamine in his quest for an alternative chemical method to synthesize hydrastinine. The molecule was patented on December 24, 1912, but was never tested on humans. With the outbreak of World War I, Köllisch was recruited…
Microdosing LSD for the Treatment of Anxiety in Dogs
Lucas Fernández Borkel participated in the first edition of Fuertedélica in 2022. This year, this Philosophy professor returns to Corralejo, this time as a founding member of the Psychedelic Scientific Association, based in Las Palmas de Gran Canaria. In this interview, Borkel shares some of the research being conducted by the association, including a pioneering…
“New psychoactive substances are poor substitutes for classics like MDMA”
Fernando Caudevilla, also known as Doctor X, will be speaking at Fuertedélica, the Psychedelic Conference of Fuerteventura, about one of his favorite molecules, MDMA, a substance that is making its way back into psychologists’ offices after reigning on the dance floors for four decades. We talked with Doctor X about MDMA culture, new chemical drugs,…
